AUSSEDAT
Tours, France
Location status: Recruiting
Location contact
CHARLES AUSSEDAT
CONTACT
NCT Number: NCT06407102
Treatment and prevention of respiratory infections are of great interest in many medical areas. Create a physical device covered by primary human nasal cells could be very usefull in order to analyse delivery and efficiency of drugs. In this context the aim of this project is to create a collection of primary cells from the human nasal epithelium.
This collection will be realised during programmed surgery, thanks to a specific device dedicated to collect nasal cells. Then the cells will be sent to the lab in order to grow at the air-liquid interface, which is an excellent 'ex vivo' model for their study.
Interested in participating?
Request Info18 year–90 year
All sexes
Interventional
Not applicable
Tours, France
Location status: Recruiting
CHARLES AUSSEDAT
CONTACT
The treatment and prevention of respiratory infections caused by emerging viruses or antibiotic-resistant bacteria are major societal and medical challenges. Inhalation allows drugs to be administered in the form of a spray or aerosol, directly into the respiratory tract (nose or lung). This is a validated approach for the non-invasive delivery of drugs to prevent and treat respiratory diseases, particularly infectious ones. Primary human nasal cell cultures grown at the air-liquid interface are an excellent 'ex vivo' model for their study in a physiological and pathophysiological context, and for testing new therapies, including aerosols. In addition, this culture model also offers an alternative to animal experimentation.
The aim of this project is therefore to create a collection of primary cells from the human nasal epithelium.
The main objective is to obtain a minimum of 60 samples of nasal epithelial cells from patients that can be cultured in air-liquid interface. The secondary objectives are to be able to study these nasal cells under physiological and pathophysiological conditions. The cells will first be amplified to constitute a cell biobank. They will then be studied under physiological conditions (anatomical and functional characterisation). Finally, they can be used to establish different models of infection or inflammation, in order to test future aerosol drugs.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
During programmed surgery (meatotomy, septoplasty or turbinoplasty for example, or other programmed surgeries), the surgeon will take an atraumatic sample from the nasal cavity using a dedicated device (brush) from the healthy nasal mucosa.
Time frame: 6 hours
Collect nasal epithelial cells that can be grown in vitro in an air-liquid interface
Time frame: 3 years
Percentage of samples that can actually be cultivated following transfer to the laboratory.
Contact information is provided by the study sponsor or research team.
Adeline Mousset
CONTACT
Charles Aussedat, MD
CONTACT
University Hospital, Tours
Other
Collection of Primary Human Nasal Epithelial Cells
Acronym: BIONOSE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06731881
Infections, Light; Therapy, Complications
London, United Kingdom
View Trial DetailsNCT06867302
Agitation, Emergence, Confusion
Al Fayyum, Faiyum Governorate, Egypt
View Trial DetailsNCT06507202
Laryngeal Disease, Laryngeal Diseases
Gyeonggi-do, Gwangmyeon-si, South Korea
View Trial DetailsNCT07056582
Nose Diseases, Otorhinolaryngologic Diseases
Sohag, Egypt
View Trial Details